NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials

By Nikita Chaurasia  | Date: 2020-08-03

NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials

U.S.-based pharmaceutical company NeuroRx Inc., along with Relief Therapeutics Holding AG, a Swiss drug development company, have reportedly declared that aviptadil (RLF-100) clinical trials have showcased quick recuperation of respiratory failures among critical patients of COVID-19. According to independent researchers, RLF-100 apparently blocks the multiplication of the SARS coronavirus in human lung cells as well as monocytes.

The first rapid clinical recuperation report was posted by doctors from Houston Methodist Hospital. It described the recovery of a 54-year-old man who contracted COVID-19 while being treated for rejection of a multiple lung transplant and was taken off the ventilator within four days of treatment.

Similar outcomes were observed in more than 15 cases treated under emergency use IND (Investigational New Drug), sources claimed. The FDA extended its access protocols which are available to critically ill patients admitted to the current Phase 2/3 FDA trials

Sources with relevant information cited that critically ill COVID-19 patients witnessed a quick recovery from pneumonitis, as displayed by the findings on their x-ray reports. Moreover, an improvement in the patients’ blood oxygen levels were seen alongside a 50% decrease in test center markers related to COVID-19 inflammation.

Prof. Jonathan Javitt, CEO and Chairman of NeuroRx was reported stating that other antiviral agents have failed to show such fast recuperation from a viral disease and exhibited inhibitions towards the multiplication of the virus. He further said that placebo-controlled trials are being carried out by NeuroRx in order to analyze the observations made during open-label and case-control studies.

For those uninitiated, RF-100 is an antiviral agent that has been developed as a Material Threat Medical Countermeasure.

The FDA has reportedly granted Fast Track designation to this antiviral, which is developed through a joint venture agreement among National Institute of Health and numerous other federal agencies, the medicine is being developed as a Material Threat Medical Countermeasure.

 

Source Credits: https://www.prnewswire.com/news-releases/rlf-100-aviptadil-clinical-trial--showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in-human-lung-cells-301104384.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Pacific Island pushes Japan to delay wastewater release from Fukushima

Pacific Island pushes Japan to delay wastewater release from Fukushima

By Nikita Chaurasia

Pacific Island nations have reportedly pushed Japan to postpone the release of Fukushima nuclear power plant wastewater due to concerns that it may pollute fishing grounds. An appeal was made on Wednesday when Japan announced that treated sewage f...

Activist groups take Danone to court over excessive use of plastics

Activist groups take Danone to court over excessive use of plastics

By Nikita Chaurasia

Danone, the French bottled water and yogurt firm, is reportedly being sued in court by three environmental activists’ groups for failing to cut its plastic footprint significantly. According to the groups, the maker of Evian and Volvic miner...

Bosch expands security with dashcams designed for rideshare drivers

Bosch expands security with dashcams designed for rideshare drivers

By Nikita Chaurasia

Bosch, the German technology company, has reportedly expanded its security footprint in the ridesharing market with the launch of its latest security dashcams. At CES 2023, Las Vegas, the German tech firm unveiled a new integrated smart camera on ...

Australia: PM Albanese denies potential $450M payout to Rio Tinto

Australia: PM Albanese denies potential $450M payout to Rio Tinto

By Nikita Chaurasia

Australia's Prime Minister Anthony Albanese has reportedly denied rumors that Rio Tinto and its partners could receive a $450 million settlement for the Gladstone power station, which would bring the total compensation for the coal price limit to...

UK: Firms still struggle with post-Brexit trading and red tape

UK: Firms still struggle with post-Brexit trading and red tape

By Nikita Chaurasia

Businesses in the UK are still reportedly grappling after two years following the beginning of post-Brexit trading, as suggested by a new report. According to the British Chambers of Commerce (BCC), firms are still battling increased red tape and ...